{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:28:12Z","timestamp":1761560892941,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2004]]},"DOI":"10.1007\/s10156-004-0303-9","type":"journal-article","created":{"date-parts":[[2004,5,24]],"date-time":"2004-05-24T07:35:14Z","timestamp":1085384114000},"page":"97-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis"],"prefix":"10.1016","volume":"10","author":[{"given":"Tetsunari","family":"Kihira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"RR-4","key":"10.1007\/s10156-004-0303-9_bib0005","first-page":"1","volume":"49","year":"2000","journal-title":"Morbid Mortal Wkly Rep"},{"key":"10.1007\/s10156-004-0303-9_bib0010","first-page":"889","article-title":"Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001","volume":"50","year":"2001","journal-title":"Morbid Mortal Wkly Rep"},{"key":"10.1007\/s10156-004-0303-9_bib0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/AAC.29.3.501","article-title":"Tissue penetration of ciprofloxacin after single and multiple doses","volume":"29","author":"LeBel","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-004-0303-9_bib0020","first-page":"140","article-title":"Phase I study with BAY o 9867 (ciprofloxacin)","volume":"33","author":"Kobayashi","year":"1985","journal-title":"Chemotherapy"},{"key":"10.1007\/s10156-004-0303-9_bib0025","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3999\/jscpt.23.515","article-title":"Phase I study of levofloxacin, (S)-(\u2013)-ofloxacin","volume":"23","author":"Nakashima","year":"1992","journal-title":"Jpn J Clin Pharmacol Ther"},{"key":"10.1007\/s10156-004-0303-9_bib0030","first-page":"43","article-title":"Pharmacokinetics of sparfloxacin in man","volume":"6","author":"Sakashita","year":"1991","journal-title":"Xenobio Metabol Dispos"},{"issue":"S-4","key":"10.1007\/s10156-004-0303-9_bib0035","first-page":"202","article-title":"Clinical studies on AM-713","volume":"29","author":"Ueda","year":"1981","journal-title":"Chemotherapy"},{"issue":"S-9","key":"10.1007\/s10156-004-0303-9_bib0040","first-page":"158","article-title":"Phase I study of T-3262, a new pyridonecarboxylic acid derivative","volume":"36","author":"Nakashima","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1007\/s10156-004-0303-9_bib0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/AAC.27.3.353","article-title":"Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine","volume":"27","author":"Joos","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-004-0303-9_bib0050","unstructured":"Labeling of Cravit Tablets (levofloxacin). Daiichi Pharmaceutical Co., Ltd., 2003."},{"issue":"S-9","key":"10.1007\/s10156-004-0303-9_bib0055","first-page":"143","article-title":"Serum protein binding of T-3262","volume":"36","author":"Yasuda","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1007\/s10156-004-0303-9_bib0060","first-page":"36","article-title":"In vitro and in vivo antibacterial activity of levofloxacin","volume":"40","author":"Nishino","year":"1992","journal-title":"Chemotherapy"},{"issue":"S-4","key":"10.1007\/s10156-004-0303-9_bib0065","first-page":"59","article-title":"In vitro and in vivo antibacterial activities of sparfloxacin, a new quinolone","volume":"39","author":"Nishino","year":"1991","journal-title":"Chemotherapy"},{"issue":"S-2","key":"10.1007\/s10156-004-0303-9_bib0070","first-page":"55","article-title":"In vitro and in vivo antibacterial activity of fleroxacin, a new synthetic antimicrobial agent","volume":"38","author":"Nishino","year":"1990","journal-title":"Chemotherapy"},{"issue":"S-9","key":"10.1007\/s10156-004-0303-9_bib0075","first-page":"68","article-title":"In vitro and in vivo antibacterial activities of T-3262, a new synthetic antimicrobial agent","volume":"36","author":"Nishino","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1007\/s10156-004-0303-9_bib0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0732-8893(90)90093-B","article-title":"Extravascular penetration of ciprofloxacin","volume":"13","author":"Bergan","year":"1990","journal-title":"A review, Diagn Microbiol Infect Dis"},{"key":"10.1007\/s10156-004-0303-9_bib0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-199528020-00005","article-title":"The importance of pharmacokinetic\/pharmacodynamic surrogate markers to outcome","volume":"28","author":"Hyatt","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1007\/s10156-004-0303-9_bib0090","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","article-title":"Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients","volume":"37","author":"Forrest","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-004-0303-9_bib0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.279.2.125","article-title":"Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials","volume":"279","author":"Preston","year":"1998","journal-title":"JAMA"},{"key":"10.1007\/s10156-004-0303-9_bib0100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00003088-200140030-00003","article-title":"Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacerials","volume":"40","author":"Aminimanizni","year":"2001","journal-title":"Clin Pharmakokinet"},{"key":"10.1007\/s10156-004-0303-9_bib0105","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax","volume":"167","author":"Friedlander","year":"1993","journal-title":"J Infect Dis"},{"key":"10.1007\/s10156-004-0303-9_bib0110","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/infdis\/166.5.1184","article-title":"Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys","volume":"166","author":"Kelly","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1007\/s10156-004-0303-9_bib0115","first-page":"1496","article-title":"Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys","volume":"36","author":"Siefert","year":"1986","journal-title":"Arzneim-Forsch"},{"key":"10.1007\/s10156-004-0303-9_bib0120","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003088-200241100-00004","article-title":"Clinical role of protein binding of quinolones","volume":"41","author":"Berezin","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1007\/s10156-004-0303-9_bib0125","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/00365549109024319","article-title":"Antimicrobial susceptibility of Bacillus anthracis","volume":"23","author":"Doganay","year":"1991","journal-title":"Scand J Infect Dis"},{"key":"10.1007\/s10156-004-0303-9_bib0130","first-page":"12","volume":"23","author":"Hirose","year":"2002","journal-title":"Infect Agents Surveil Rep"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X04710776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X04710776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10156-004-0303-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:44:36Z","timestamp":1761158676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X04710776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004]]}},"alternative-id":["S1341321X04710776"],"URL":"https:\/\/doi.org\/10.1007\/s10156-004-0303-9","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2004]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s10156-004-0303-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}